SEMINARS IN LIVER DISEASE is a premier journal dedicated to advancing the field of hepatology, published by THIEME MEDICAL PUBL INC. Established in 1981, it has become a respected resource within the academic community, providing high-quality peer-reviewed articles that cover a broad range of topics related to liver diseases. With an impressive impact factor and recognized as a Q1 journal in the hepatology category, it ranks 17th out of 82 journals in the field, placing it in the top 21% of its category according to Scopus rankings. Although it does not offer open access, the journal’s rigorous standards and extensive network ensure that it reaches a wide audience of clinicians, researchers, and students, fostering knowledge and innovation in liver disease management. The journal's objectives focus on disseminating critical insights and promoting informed discussions that can pave the way for future research and clinical advancements in hepatology.

Hepatic Oncology is a premier Open Access journal published by Future Medicine Ltd that specializes in the critical intersection of hepatology and oncology. With a focus on advancing knowledge in the diagnosis and treatment of liver cancers, the journal provides a platform for innovative research, reviews, and clinical perspectives that serve as a valuable resource for researchers, clinicians, and students alike. Established in 2016 and evolving over the years, Hepatic Oncology underscores its commitment to accessible scientific communication, having transitioned to open access in 2018 to reach a broader audience. The journal holds a Q4 quartile ranking in the fields of hepatology and oncology for 2023, reflecting its emerging influence and role in contemporary research. Through high-quality articles and a focus on real-world applications, Hepatic Oncology aims to bridge gaps in knowledge while fostering collaboration among professionals dedicated to enhancing patient care in hepatic malignancies.

Cellular and Molecular Gastroenterology and Hepatology, published by Elsevier Inc, is a premier Open Access journal dedicated to advancing the understanding and treatment of gastrointestinal and liver diseases. Since its inception in 2015, this journal has established itself as a leading publication within its field, boasting impressive metrics with a 2023 Q1 ranking in both Gastroenterology and Hepatology. It ranks #10 out of 167 in Gastroenterology and #11 out of 82 in Hepatology on Scopus, placing it in the 94th and 87th percentiles, respectively. This journal aims to disseminate high-quality, peer-reviewed research that fosters innovative solutions for clinical challenges, making it an invaluable resource for researchers, healthcare professionals, and students alike. With open access, all published content is readily available to a global audience, ensuring that critical findings in cellular and molecular biology related to gastroenterology and hepatology reach those who can benefit the most from the latest advances in the field. For more information, please visit us at our address in San Diego, CA, or explore our articles online.

Welcome to the JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, an esteemed publication in the field of gastroenterology and hepatology, proudly published by WILEY. Established in 1986, this journal serves as a crucial platform for researchers, healthcare professionals, and students, presenting groundbreaking research and comprehensive reviews that drive advances in understanding and treating gastrointestinal and liver diseases. With a strong reputation evidenced by its Q1 ranking in gastroenterology and Q2 ranking in hepatology, this journal ranks impressively in the Scopus metrics - positioned at #22 out of 167 in gastroenterology and #21 out of 82 in hepatology, reflecting its contribution to scholarly excellence. Although it does not offer open access options, the journal’s rich archive and diverse topics make it indispensable for those dedicated to improving patient outcomes in these critical areas of medicine. Whether you are a seasoned researcher or an aspiring medical professional, engaging with this journal will keep you at the forefront of the latest developments and emerging trends in gastroenterology and hepatology research.

HEPATOLOGY is a premier scholarly journal dedicated to advancing the field of liver research and clinical practice. Published by Lippincott Williams & Wilkins, this journal boasts an impressive impact factor and holds a prestigious position as one of the top-ranked publications in both Hepatology (Q1) and Medicine (miscellaneous, Q1) categories as of 2023. HEPATOLOGY, with its commitment to disseminating high-quality research since its inception in 1981, serves as an essential platform for researchers, clinicians, and students focusing on liver diseases, including hepatitis, cirrhosis, and liver cancer. The journal's editorial board comprises leading experts who guide the publication towards its objective of fostering innovation and collaboration in this critical area of health. Although it does not offer an open access model, HEPATOLOGY ensures that its comprehensive analyses, reviews, and groundbreaking studies are accessible to the global medical community. Join the discourse in hepatology and be a part of a transformative journey through this indispensable resource.

JOURNAL OF HEPATOLOGY, published by Elsevier, stands as a preeminent source in the field of Hepatology, with its impact underscored by a remarkable 2023 Category Quartile of Q1 and a Scopus rank of 3rd out of 82 journals, placing it in the 96th percentile for the discipline. Since its inception in 1985, this journal has been a vital conduit for the dissemination of pioneering research, clinical studies, and reviews related to liver diseases and their impact on global health. Although it currently does not offer open access options, the journal is committed to providing top-tier content to its readership—researchers, medical professionals, and students—in order to advance knowledge and foster innovation in hepatology. With a broad and inclusive scope, it aims to cover significant breakthroughs, therapeutic advancements, and epidemiological studies, continually pushing the boundaries of understanding in liver health. The journal is based in Amsterdam, Netherlands, and remains an essential resource for those dedicated to the progression of hepatologic science.

Canadian Journal of Gastroenterology and Hepatology, published by HINDAWI LTD, serves as a vital resource in the fields of gastroenterology and hepatology. Since its inception in 1987, this open-access journal has made significant contributions to advancing research and clinical practice through its comprehensive coverage of topics ranging from liver diseases to gastrointestinal disorders. With an impressive Q2 ranking in Gastroenterology and a Q3 ranking in Hepatology as of 2023, the journal has established itself as an influential platform for researchers and healthcare professionals seeking to disseminate and acquire knowledge. The journal is based in Egypt, with its operational headquarters located in London, England. Notably, it holds a respectable standing in Scopus rankings, placed at Rank #64 in Gastroenterology and Rank #34 in Hepatology, reflecting its impact and relevance in the medical community. With a commitment to quality and accessibility, the Canadian Journal of Gastroenterology and Hepatology continues to foster innovation and collaboration among its readers.

The International Journal of Hepatology, published by HINDAWI LTD, is a premier open-access journal dedicated to the field of hepatology. Since its inception, this journal has championed the dissemination of cutting-edge research and reviews pertaining to liver health, diseases, and therapies. With an ISSN of 2090-3448, the journal has been committed to open-access publishing since 2011, ensuring that vital knowledge is readily available to researchers, clinicians, and students worldwide. Based in Egypt, this journal stands out in its category, achieving a Q3 ranking in 2023 within the scope of Hepatology by Scopus, which ranks it #43 out of 82 in the field. The International Journal of Hepatology offers a platform for significant findings and discussions that influence clinical practices and foster new research directions, thus playing a crucial role in advancing the understanding of liver diseases and their management.

Hepatology Communications, published by Lippincott Williams & Wilkins, serves as a pioneering platform in the field of hepatology, dedicated to advancing the understanding of liver diseases and treatments. Since its inception in 2017, this open access journal has rapidly gained recognition, achieving an impressive Q1 ranking in Hepatology as of 2023, and appealing to a diverse audience of researchers, clinicians, and students alike. With its focus on high-quality research and clinical studies, the journal aims to facilitate impactful discussions and disseminate vital findings that address the challenges faced in liver health. Operating out of the United States, and accessible globally, Hepatology Communications is committed to fostering a collaborative research environment and enhancing the visibility of scholarly work in hepatology, ultimately driving forward innovations in patient care and treatment strategies.

The Journal of Hepatocellular Carcinoma is a pivotal open-access publication dedicated to advancing the field of hepatocellular carcinoma research. Published by DOVE MEDICAL PRESS LTD since 2014, this journal seeks to disseminate high-quality articles that explore innovative treatments, clinical trials, and emerging research in the context of liver cancer. With its ISSN: N/A and E-ISSN: 2253-5969, the journal is optimized for a global audience, ensuring accessibility to a broad spectrum of researchers, healthcare professionals, and students engaged in oncology and hepatology. While its Scopus ranking places it in the lower quartiles of the respective fields, the journal continues to strive for growth and visibility in a rapidly evolving landscape. The Journal of Hepatocellular Carcinoma is an essential resource for anyone seeking to enhance their understanding of liver diseases and contribute to the fight against hepatocellular carcinoma.